TESARO® logo_RGB_small.png
TESARO Announces Approval of VARUBY® (Oral Rolapitant Tablets) by European Commission
April 26, 2017 08:30 ET | TESARO, Inc.
VARUBY provides protection for delayed chemotherapy-induced nausea and vomiting (CINV) with a single dose as part of an antiemetic regimenUp to 50% of patients undergoing highly or moderately...
TESARO® logo_RGB_small.png
TESARO Receives Positive CHMP Opinion for VARUBY®
February 27, 2017 02:00 ET | TESARO, Inc.
WALTHAM, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the European Medicines Agency’s (EMA) Committee for...